Nls pharmaceutics announces technology patent grant covering mazindol for treatment of attention deficit hyperactivity disorder and rare sleep disorders in hong kong

Hong kong patent relates to company's lead product candidate, mazindol er (extended-release) use in narcolepsy, idiopathic hypersomnia (ih) and attention deficit hyperactivity disorder (adhd) further supports nls global strategy with key patents now granted in major markets including hong kong, japan, south korea, the u.s., europe & canada nls has accelerated ongoing clinical development of its lead product, quilience® (mazindol er) for the treatment of rare sleep disorders zurich, switzerland / accesswire / january 10, 2023 / nls pharmaceutics ltd. (nasdaq:nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that the patents registry, intellectual property department of the government of the hong kong special administrative region has granted approval for patent application 42022055879.5, which covers mazindol er as a method of treatment for adhd.
NLSP Ratings Summary
NLSP Quant Ranking